APUS Stock Forecast: Apimeds Pharmaceuticals US, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Apimeds Pharmaceuticals US, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (44): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Volatility (6): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
APUS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on APUS, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
APUS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
APUS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.5×
- EV / EBITDA
- —
Cheaper than 37% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −3.9%
- Return on assets
- −3.7%
- Dividend yield
- —
Higher than 41% of US stocks
Higher than 34% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Apimeds Pharmaceuticals US, Inc. has a market value of $3.0M and an enterprise value of $9.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$58.2M.
Free cash flow in the twelve months to 30 June 2026: −$13.3M.
Apimeds Pharmaceuticals US, Inc. employs 2 people.
Data provided by Twelve Data
APUS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at APUS’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Apimeds Pharmaceuticals US, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about APUS
How does Ticker Nerd's model rank APUS?
As at 21 Nov 2026, Apimeds Pharmaceuticals US, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (44 of 100).
What is the APUS stock forecast for 2030?
No analyst covering Apimeds Pharmaceuticals US, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APUS are extrapolating price history, which says nothing about the business.
What does Apimeds Pharmaceuticals US, Inc. do?
Apimeds Pharmaceuticals US Inc. is a clinical-stage biopharmaceutical company focused on developing Apitox, a purified bee venom-based therapeutic candidate delivered intradermally. The company is primarily working on treatments for inflammation and pain management, with an emphasis on knee osteoarthritis and, to a lesser extent, multiple sclerosis.
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US Inc. is a clinical-stage biopharmaceutical company focused on developing Apitox, a purified bee venom-based therapeutic candidate delivered intradermally. The company is primarily working on treatments for inflammation and pain management, with an emphasis on knee osteoarthritis and, to a lesser extent, multiple sclerosis. Its current business centers on advancing this non-narcotic drug candidate through clinical development and related pharmaceutical activities. Apimeds Pharmaceuticals US Inc. also operates as part of a broader biopharmaceutical platform that includes research, development, and potential commercialization capabilities. Headquartered in Matawan, New Jersey, the company is positioned within the specialty drug manufacturing and biotechnology markets, where its work targets high-need conditions in musculoskeletal and inflammatory care.
CEO Dr. Vinod Menon · 2 employees · United States · https://www.mindwavedao.com